DrugRepurposing Online is a proprietary database, created by Numedicus, for finding new uses for existing compounds, containing both existing and abandoned drugs. Importantly, it is differentiated from other attempts to link molecules, targets and diseases, by focussing functional, experimentally validated content. On-line access for registered users to this search engine for finding secondary uses for such compounds is available through this portal.

Levels of database access

There are various levels of access, both free (restricted) and premium; the latter is available either by paying or by contributing. Users can add new examples of drug repurposing and receive rewards which may be used to offset — either in part, or in full — subscriptions to the database. In this way, DrugRepurposing Online is a community of like-minded investigators, and also a gold standard crowdsourced resource for this most efficient and attractive strategy for medicinal innovation.

Database content

This database contains 9040 compounds which have been either launched, registered or investigated, covering 474 indications, with 1002 mechanisms. There are 3052 links between mechanism and indication, 831 links between compound and indication and 275 links between compound and mechanism -- so-called "off-target" effects. Overall this gives rise to 4158 repurposing opportunities for further consideration.

The database is populated with 4599 literature references, of which 1024 derive from prospective clinical studies or case reports, 231 from retrospective or case control analyses, 2017 are from pharmacological in vivo studies and 466 are from patents. The rest are in vitro studies or genomic associations.

The original Drugrepurposing Online database has recently been supplemented with access to information from the Guide to Pharmacology database (under a Creative Commons Attribution-ShareAlike 4.0 International License). Through this integration, Drugrepurposing Online has been supplemented with 9859 compounds (albeit, there is some overlap with existing information), and 19082 new interactions between compounds and mechanisms.

Next...

Latest News